NCT00950586

Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702

A Placebo-controlled, Single-blind, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Drug Interaction of GSK1034702 After Repeat Doses in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated doses of the study medicine. The study will investigate the following questions, do repeated doses of the study medicine have any important side effects when taken by mouth? How much of the study medicine gets into the bloodstream, and how quickly does the body get rid of it? Does the study medicine affect memory, attention and problem-solving skills? What are the effects when the study medicine and dextromethorphan are taken together.

Conditions

• Cognitive Disorders

Interventions

Type	Name	Description
DRUG	GSK1043702	Oral dose in liquid or tablet formulation
DRUG	Dextromethorphan	30mg Oral dose
DRUG	Placebo	To match GSK1034702

Timeline

• Start date: 2009-08-24
• Primary completion: 2009-12-24
• Completion: 2009-12-24
• First posted: 2009-08-03
• Last updated: 2017-07-13

Locations

1 site across 1 country: United Kingdom